Obesity may be a predictor of prostate cancer recurrence
Moderately and severely obese prostate cancer patients had a 99% greater risk of developing biochemical failure than other patients, according to the authors of a study from the University of Texas M.D. Anderson Cancer Center, Houston.
Moderately and severely obese prostate cancer patients had a 99% greater risk of developing biochemical failure than other patients, according to the authors of a study from the University of Texas M.D. Anderson Cancer Center, Houston. They also found that obese patients had a 66% increased risk of having a tumor that recurs or becomes metastatic than did non-obese patients.
The study is scheduled for publication in the Aug. 1 issue of Cancer.
The study, coupled with an M.D. Anderson study released last year showing that a history of weight gain or obesity at the time of diagnosis also played a role in how aggressive prostate cancer may become after surgery (Clin Cancer Res 2005; 11:6889-94), suggests that a patient’s weight should be a factor when considering follow-up and treatment.
"When patients and their physicians are uncertain about the need for further therapy, our research indicates that a man's weight should be factored into that decision," said Sara Strom, PhD, lead author of both studies.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
